biostudies-literatureBrunner EFDA HHSFood and Drug Administration2814-2859https://www.ebi.ac.uk/biostudies/studies/S-EPMC12463801biostudies-literatureUnknown40(12)<h4>Description</h4>The American Society of Addiction Medicine (ASAM) has partnered with nine other medical societies and professional associations representing a wide range of clinical settings and patient populations to provide guidance on evidence-based strategies for tapering benzodiazepine (BZD) medication across a variety of settings.<h4>Methods</h4>The guideline was developed following modified GRADE methodology and clinical consensus process. The process included a systematic literature review as well as several targeted supplemental searches. The clinical practice guideline was revised based on external stakeholder review.<h4>Recommendations</h4>Key takeaways included the following: Clinicians should engage in ongoing risk-benefit assessment of BZD use/tapering, clinicians should Journal of general internal medicineJoint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits.PMC12463801U01FD007804Sanders AEBrunner EKlein TASAM Staff and ContractorsVandenBerg ASnodgrass BDevoto ANorrington JFramnes-DeBoer SMaust DChen CAMecca MRajneesh KFWright TMazer-Amirshahi MBoyle MClinical Guideline Committee (CGC) MembersOgbonna CKleykamp BLindsay DRoll ENajera DfalseJoint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits.<h4>Description</h4>The American Society of Addiction Medicine (ASAM) has partnered with nine other medical societies and professional associations representing a wide range of clinical settings and patient populations to provide guidance on evidence-based strategies for tapering benzodiazepine (BZD) medication across a variety of settings.<h4>Methods</h4>The guideline was developed following modified GRADE methodology and clinical consensus process. The process included a systematic literature review as well as several targeted supplemental searches. The clinical practice guideline was revised based on external stakeholder review.<h4>Recommendations</h4>Key takeaways included the following: Clinicians should engage in ongoing risk-benefit assessment of BZD use/tapering, clinicians should 2025-01-01T00:00:00Z2025 Sep2026-06-03T20:23:19.526Z2026-05-01T03:10:09.142ZS-EPMC124638014052620410.1007/s11606-025-09499-2